Introduction
============

COPD was the tenth most common cause of disease-related deaths in Japan in 2014, and it was found that the number of COPD-related deaths is increasing.[@b1-copd-11-2543] An epidemiological survey in Japanese population revealed that the prevalence of physician-diagnosed COPD in Japan is increasing, and \~8.6% of the patients aged ≥40 years are suffering from COPD. An estimated population of 5.3 million Japanese are now at risk of developing COPD; however, only a small proportion (9.4%) were diagnosed to have COPD.[@b2-copd-11-2543],[@b3-copd-11-2543]

Decline in quality of life due to breathlessness is the major challenge in the management of COPD that demands sustained improvement in lung function.[@b4-copd-11-2543] Long-acting bronchodilators of different pharmacological classes, either as monotherapy or in combination, are now the preferred choice and proven cornerstone for treating compromised airflow in patients with COPD.[@b4-copd-11-2543] In situations where a single bronchodilator fails to provide the desired effect, both Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy and Japanese Respiratory Society (JRS) guidelines recommend the use of a fixed-dose combination of a long-acting β~2~-agonist (LABA) and a long-acting muscarinic antagonist (LAMA) for management of symptomatic patients with COPD.[@b4-copd-11-2543],[@b5-copd-11-2543] A fixed-dose LABA/LAMA combination, indacaterol (IND)/glycopyrronium (GLY), was evaluated in 14 controlled trials as maintenance treatment for patients with COPD. Outcomes of these studies demonstrated better efficacy of IND/GLY in terms of improving lung function and quality of life, with a comparable safety profile versus placebo,[@b6-copd-11-2543]--[@b8-copd-11-2543] LAMA, open-label tiotropium (TIO),[@b9-copd-11-2543] and a combination of LABA/inhaled corticosteroid (ICS) and salmeterol/fluticasone (50/500 μg) in patients with moderate-to-severe COPD. Most of these trials have been conducted in Caucasian patients; however, two studies, SHINE and ARISE, evaluated the efficacy of IND/GLY in a Japanese patient subgroup as well.[@b10-copd-11-2543],[@b11-copd-11-2543] In the overall population of the SHINE study, IND/GLY showed superior improvements in lung function and health status compared with placebo, IND, GLY, and open-label TIO with a similar safety profile in patients with COPD.[@b10-copd-11-2543] Here, we report the efficacy and safety of IND/GLY in the Japanese subgroup of patients from the SHINE study.

Methods
=======

SHINE was a 26-week, multicenter, randomized, double-blind, parallel-group, placebo- and active-controlled study ([www.ClinicalTrial.gov](http://www.ClinicalTrial.gov) identifier NCT01202188).[@b10-copd-11-2543] After the eligibility assessments, patients were randomized (2:2:2:2:1) to receive once daily (od) IND/GLY 110/50 μg, IND 150 μg, GLY 50 μg, open-label TIO 18 μg, or matching placebo. IND/GLY, IND, GLY, and placebo were administered via the Breezhaler^®^ device, whereas TIO was delivered via the HandiHaler^®^ device. Men and women aged ≥40 years with moderate-to-severe stable COPD and a smoking history of ≥10 pack-years who had a postbronchodilator forced expiratory volume in 1 second (FEV~1~) ≥30% and \<80% of predicted normal value and a postbronchodilator FEV~1~/forced vital capacity ratio \<0.70 were included in the study. The key exclusion criterion was COPD exacerbation that required treatment with antibiotics, systemic steroids (oral or intravenous), or hospitalization during 6 weeks prior to screening or before randomization. During the study, salbutamol/albuterol was permitted as a rescue medication. Informed consent was taken from all the eligible patients. The study was performed in accordance with the Declaration of Helsinki, Good Clinical Practice guidelines, and all applicable regulatory requirements and was approved by the Ministry of Health, Labor and Welfare, Japan, as well as all relevant national and local ethics review boards ([Table S1](#SD1-copd-11-2543){ref-type="supplementary-material"}).

Assessments
-----------

The primary end point of the study was trough FEV~1~ (mean of FEV~1~ values measured at 23 hours 15 minutes and 23 hours 45 minutes) after IND/GLY administration at Week 26 versus IND and GLY. Other key end points included peak FEV~1~, area under the curve for FEV~1~ from 5 minutes to 4 hours (FEV~1~ AUC~5\ min--4\ h~), and trough FEV~1~ throughout the study period. Nonspirometric analysis included the Transition Dyspnea Index (TDI) focal score and St George's Respiratory Questionnaire (SGRQ) total score at Week 26. Safety was assessed by monitoring adverse events (AEs) and serious AEs over the 26-week study period.

Statistical analysis
--------------------

Data were analyzed using a linear mixed model, which included FEV~1~ as the dependent variable, treatment as an fixed effect, the variables (FEV~1~, ICS use, FEV~1~ reversibility components, and smoking status) at baseline as covariates, and centre as a random effect. The estimated treatment differences were presented as least-squares mean with standard errors and the associated 95% confidence interval. The secondary efficacy variables, which included peak FEV~1~, FEV~1~ AUC~5\ min--4\ h~, trough FEV~1~ over 26 weeks, TDI focal score, and SGRQ total score, were also analyzed using the same mixed model as specified for the analysis of the primary variable, with the appropriate baseline measurement included as a covariate.[@b10-copd-11-2543] In addition, the proportions of patients who achieved a clinically important improvement in the SGRQ and TDI focal score were analyzed using logistic regression as specified for the analysis of the primary variable, with the appropriate baseline measurement included as a covariate.

Results
=======

Patient characteristics
-----------------------

Of the total 2,144 patients randomized in the SHINE study, 182 (8.5%) were Japanese and randomized to receive IND/GLY 110/50 μg (n=42), IND 110 μg (n=41), GLY 50 μg (n=40), open-label TIO 18 μg (n=40), and matching placebo (n=19). The baseline demographic and clinical characteristics of the patients were comparable across all the groups ([Table 1](#t1-copd-11-2543){ref-type="table"}). More than 90% of the patients in the Japanese cohort were men aged \>68 years, and their mean percentage of predicted postbronchodilator FEV~1~ was \~60%, with only 19% reversibility of FEV~1~ after bronchodilation. More than 75% of patients had moderate-to-severe COPD according to the GOLD 2009 guidelines, and almost 10% of patients in the Japanese subgroup were having a history of COPD exacerbation in the previous year and \~25% were using ICS at baseline. In total, 160 patients (87.9%) completed the study; the major reasons for discontinuation from the study were AEs and withdrawal of consent by the patients ([Figure 1](#f1-copd-11-2543){ref-type="fig"}).

Lung function
-------------

The primary efficacy end point of the SHINE study was achieving a 190 mL improvement in trough FEV~1~ from baseline with IND/GLY in Japanese patients. Improvement in lung function was greater in Japanese patients treated using IND/GLY compared with IND (90 mL), GLY (100 mL), TIO (90 mL), and placebo (280 mL; [Figure 2](#f2-copd-11-2543){ref-type="fig"}).[@b10-copd-11-2543] The spirometric profile in terms of trough FEV~1~ with IND/GLY was superior compared with TIO and placebo on Day 2 and Week 26, with treatment differences ranging from 90 mL to 290 mL ([Figure 3](#f3-copd-11-2543){ref-type="fig"}). IND/GLY showed greater improvements in peak FEV~1~ from 5 minutes to 4 hours compared with IND, GLY, TIO, and placebo at Week 26, with treatment differences ranging from 100 mL to 390 mL (all *P*\<0.01; [Figure 4](#f4-copd-11-2543){ref-type="fig"}). In addition, an improvement in lung function was also observed with IND/GLY in terms of FEV~1~ AUC~5\ min--4\ h~ compared with IND, GLY, TIO, and placebo, at the end of study, with treatment differences ranging from 90 mL to 380 mL (all *P*\<0.05; [Figure 5](#f5-copd-11-2543){ref-type="fig"}).

Patient-reported outcomes
-------------------------

Dyspnea control in terms of improvement in TDI focal score in the Japanese subgroup was comparable across all treatment groups. Treatment differences between IND/GLY versus placebo were 0.67 units and versus IND, GLY, TIO were 0.69 units, 0.03 units, and 0.65 units, respectively. A higher proportion of patients achieved a clinically meaningful improvement in the TDI focal score (≥1 unit) with IND/GLY versus IND (odds ratio \[OR\], 1.60), GLY (OR, 1.01), TIO (OR, 1.16), and placebo (OR, 1.15).

Improvement in health status assessed via reduction in the SGRQ total score was similar across all treatment groups in the Japanese patient subgroup. Treatment differences in the SGRQ total score between IND/GLY vs placebo, IND, GLY, and TIO were −1.31 units, −0.48 units, −3.75 units, and −0.96 units, respectively. The proportion of patients achieving a clinically meaningful improvement in the SGRQ total score (≥4-unit reduction) was highest with IND/GLY compared to IND (OR, 1.69), GLY (OR, 3.13), TIO (OR, 2.36), and placebo (OR, 0.86).

Safety
------

The overall incidence of AEs was similar across the five treatment groups, and the lowest incidence was reported for patients treated with IND/GLY (21 (50%); IND, 27 (65.9%); GLY, 24 (60.0%); TIO, 31 (77.5%); and placebo, 12 (63.2%); [Table 2](#t2-copd-11-2543){ref-type="table"}). COPD exacerbations were found to be the frequent AEs in all treatment groups, with their lowest occurrence in patients treated with IND/GLY (\~12%). Serious AEs were comparable across all treatment groups. Moreover, no cardiovascular AEs, major adverse cardiac events, cerebro--cardiovascular AEs, abnormal changes from baseline QTc in resting ECG was obtained using Bazett's formula (QTcB), Fridericia's formula (QTcF) (\<10 mlliseconds) or heart rate, or imbalance in hematocrit values was observed in the Japanese subgroup.

Discussion
==========

The aim of this post hoc analysis was to explore the efficacy and safety profile of IND/GLY in the Japanese subgroup of the SHINE study. Based on the overall results of the SHINE study, the efficacy of IND/GLY was superior to that of placebo, with comparable safety.[@b10-copd-11-2543] The results of this analysis support our claim that IND/GLY improves lung function and health status in patients with moderate-to-severe COPD with compromised airflow according to the GOLD guidelines, irrespective of ethnicity. The fourth edition of the JRS guidelines, which is customized for the Japanese scenario, recommend LAMA/LABA for the management of moderate-to-severe COPD with symptoms and the use of ICS in combination with LABA or LAMA only if the condition does not improve.[@b4-copd-11-2543],[@b5-copd-11-2543],[@b12-copd-11-2543] GOLD strategy that considers diverse ethnicity as well as various COPD phenotypes differs from the JRS guidelines, which are specific for the Japanese population, in terms of prescribing ICS.[@b4-copd-11-2543],[@b5-copd-11-2543] The difference in the recommendations may be due to the fact that Japanese patients with COPD experience fewer COPD exacerbations compared to Caucasians.[@b12-copd-11-2543] In the Japanese subgroup of the SHINE study, we observed greater improvements in lung function with IND/GLY versus IND, GLY, and TIO mono-therapies, although the improvement in quality of life was comparable across all groups. The results of this subgroup analysis were similar to those observed in the entire study population.[@b10-copd-11-2543] The small sample size is perhaps responsible for the lower baseline FEV~1~ observed in the TIO group (1.22 L) than the IND/GLY group (1.36 L), which was at least partially responsible for the 90 mL "treatment effect" of IND/GLY versus TIO at the end of 26 weeks. However, baseline FEV~1~ was used as a covariate in the statistical analysis, and the treatment effect was adjusted to account for the baseline difference in FEV~1~ between the IND/GLY and TIO groups. The aforementioned findings were similar to those reported in another study, wherein baseline FEV~1~ affected the treatment efficacy of a bronchodilator, which showed a smaller change from baseline FEV~1~ value in patients with lower baseline FEV~1~.[@b13-copd-11-2543] In addition to the observed improvements in trough FEV~1~, our study also demonstrated rapid bronchodilation with IND/GLY in terms of FEV~1~ AUC~5\ min--4\ h~ compared to the monotherapy components, TIO, and placebo. In previous studies, spirometric outcomes of IND/GLY treatment showed a comparable reduction in the rate of COPD exacerbations, along with superior improvement in lung function versus its monotherapy components, TIO, and salmeterol/fluticasone and without considerable variations in the TDI focal score and SGRQ total score among different treatment groups.[@b9-copd-11-2543],[@b11-copd-11-2543],[@b14-copd-11-2543],[@b15-copd-11-2543] In our study, the results of the Japanese subgroup analysis showed comparable improvements in the TDI focal score and SGRQ total score, which is consistent with the results of a previous study.[@b14-copd-11-2543] A higher proportion of patients from the IND/GLY group achieved minimal clinically important differences for TDI and SGRQ compared with the other treatment groups. Moreover, the number of patients in the Japanese subgroup was small to determine the significant improvement in the TDI focal score and SGRQ total score.

The SHINE study demonstrated that safety profile of IND/GLY in Japanese patients with COPD was consistent with the overall study population.[@b10-copd-11-2543] The most frequently reported AE was COPD exacerbation in the Japanese subgroup, and the occurrence was \~12%, which was lower compared with TIO (25%) and placebo (\~32%). Furthermore, the incidents of exacerbations were lesser in the Japanese subgroup than the overall study population, where \~39% exacerbations were reported. This fact was supported by the results of a previous study that demonstrated that IND/GLY was superior in preventing moderate-to-severe COPD exacerbations compared with TIO, with concomitant improvements in lung function and health status.[@b9-copd-11-2543] A pooled analysis of 14 randomized clinical trials with data from 11,404 patients with COPD demonstrated that IND/GLY did not increase the risk of investigated safety end points and had a comparable safety profile as its monocomponents, TIO, and placebo.[@b16-copd-11-2543]

Conclusion
==========

Based on the results of this subgroup analysis, we can conclude that the efficacy and safety of IND/GLY in the Japanese population were similar to that in the overall study population of the SHINE study; thus, IND/GLY may be considered as a treatment option for the management of Japanese patients with moderate-to-severe COPD.
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![Patient disposition.\
**Note:** n, number of patients.\
**Abbreviations:** IND, indacaterol; GLY, glycopyrronium; od, once daily; TIO, tiotropium; ol, open label.](copd-11-2543Fig1){#f1-copd-11-2543}

![Trough FEV~1~ (L) after 26 weeks in the Japanese subgroup.\
**Notes:** Data are presented as LSM (standard error). Trough FEV~1~ is defined as the average of the post dose 23 hours 15 minutes and 23 hours 45 minutes FEV~1~ values (excluding values taken outside 22 hours 45 minutes and 24 hours 15 minutes post dose) at Day 2.\
**Abbreviations:** FEV~1~, forced expiratory volume in 1 second; LSM, least-squares mean; IND, indacaterol; GLY, glycopyrronium; od, once daily; TIO, tiotropium; ∆, treatment difference.](copd-11-2543Fig2){#f2-copd-11-2543}

![Trough FEV~1~ (L) over 26 weeks in the Japanese subgroup.\
**Note:** Data are presented as LSM (standard error).\
**Abbreviations:** FEV~1~, forced expiratory volume in 1 second; LSM, least-squares mean; IND, indacaterol; GLY, glycopyrronium; od, once daily; TIO, tiotropium.](copd-11-2543Fig3){#f3-copd-11-2543}

![Peak FEV~1~ (L) from 5 minutes to 4 hours at Week 26 in the Japanese subgroup.\
**Notes:** Data are presented as LSM (standard error). Peak FEV~1~ is defined as the maximum FEV~1~ during the first 4 hours after dosing.\
**Abbreviations:** FEV~1~, forced expiratory volume in 1 second; LSM, least-squares mean; IND, indacaterol; GLY, glycopyrronium; od, once daily; TIO, tiotropium; ∆, treatment difference.](copd-11-2543Fig4){#f4-copd-11-2543}

![FEV~1~ AUC~5\ min--4\ h~ (L) at Week 26 in the Japanese subgroup.\
**Note:** Data are presented as LSM (standard error).\
**Abbreviations:** FEV~1~ AUC~5\ min-4\ h~, area under the curve for FEV~1~ from 5 minutes to 4 hours; FEV~1~, forced expiratory volume in 1 second; LSM, least-squares mean; IND, indacaterol; GLY, glycopyrronium; od, once daily; TIO, tiotropium; ∆, treatment difference.](copd-11-2543Fig5){#f5-copd-11-2543}

###### 

Demographic and baseline clinical characteristics of the Japanese subgroup

                                                                IND/GLY (n=42)     IND (n=41)         GLY (n=40)         TIO[\*](#tfn2-copd-11-2543){ref-type="table-fn"} (n=40)   Placebo (n=19)
  ------------------------------------------------------------- ------------------ ------------------ ------------------ --------------------------------------------------------- ------------------
  Age, years                                                    71.0 (6.92)        69.2 (5.96)        69.0 (8.87)        67.8 (9.25)                                               68.9 (5.22)
  Sex, male, n (%)                                              42 (100)           40 (97.6)          38 (95.0)          37 (92.5)                                                 18 (94.7)
  Body mass index, kg/m^2^                                      22.4 (3.35)        22.7 (3.17)        22.2 (3.05)        22.8 (3.54)                                               24.3 (1.86)
  Smoking history, pack-years                                   64.7 (25.21)       59.9 (27.71)       69.8 (33.36)       64.7 (38.25)                                              52.3 (20.20)
  Smoking status, n (%)                                                                                                                                                            
   Ex-smoker                                                    31 (73.8)          31 (75.6)          31 (77.5)          29 (72.5)                                                 17 (89.5)
   Current smoker                                               11 (26.2)          10 (24.4)          9 (22.5)           11 (27.5)                                                 2 (10.5)
  ICS use at baseline, n (%)                                                                                                                                                       
   No                                                           31 (73.8)          30 (73.2)          28 (70.0)          29 (72.5)                                                 14 (73.7)
   Yes                                                          11 (26.2)          11 (26.8)          12 (30.0)          11 (27.5)                                                 5 (26.3)
  Number of COPD exacerbations in the previous year, n (%)                                                                                                                         
   0                                                            39 (92.9)          32 (78.0)          31 (77.5)          33 (82.5)                                                 17 (89.5)
   1                                                            2 (4.8)            9 (22.0)           8 (20.0)           7 (17.5)                                                  1 (5.3)
   ≥2                                                           1 (2.4)            0                  1 (2.5)            0                                                         1 (5.3)
  Severity of COPD (GOLD 2008), n (%)                                                                                                                                              
   Moderate COPD                                                32 (76.2)          31 (75.6)          35 (87.5)          28 (70.0)                                                 14 (73.7)
   Severe COPD                                                  10 (23.8)          10 (24.4)          4 (10.0)           12 (30.0)                                                 5 (26.3)
  Duration of COPD, years                                       3.6 (3.23)         3.9 (5.01)         4.0 (3.80)         3.4 (2.10)                                                3.2 (2.78)
  FEV~1~, prebronchodilator, L                                  1.36 (0.44)        1.32 (0.43)        1.35 (0.41)        1.22 (0.42)                                               1.27 (0.38)
  FEV~1~, postbronchodilator, L                                 1.60 (0.42)        1.54 (0.46)        1.56 (0.42)        1.48 (0.45)                                               1.47 (0.46)
  FEV~1~ (L) postbronchodilator (% predicted FEV~1~)            61.357 (13.0941)   60.268 (14.8594)   61.300 (11.4672)   57.600 (12.8797)                                          57.474 (13.1376)
  FEV~1~ reversibility after inhalation of bronchodilator (%)   20.167 (13.3543)   18.829 (13.6874)   17.000 (12.7481)   23.800 (15.4026)                                          15.737 (9.4331)

**Note:** Data are represented as mean (standard deviation) unless otherwise specified.

Open label.

**Abbreviations:** IND, indacaterol; GLY, glycopyrronium; TIO, tiotropium; ICS, inhaled corticosteroid; FEV~1~, forced expiratory volume in 1 second; GOLD, Global Initiative for Chronic Obstructive Lung Disease.

###### 

Summary of AEs and SAEs by preferred terms in the Japanese subgroup

                                                            IND/GLY (n=42)   IND (n=41)   GLY (n=40)   TIO (n=40)   Placebo (n=19)
  --------------------------------------------------------- ---------------- ------------ ------------ ------------ ----------------
  Total AEs                                                 21 (50.0)        27 (65.9)    24 (60.0)    31 (77.5)    12 (63.2)
  AEs ≥2 incidences in any group                                                                                    
   COPD[a](#tfn5-copd-11-2543){ref-type="table-fn"}         5 (11.9)         7 (17.1)     6 (15.0)     10 (25.0)    6 (31.6)
   Nasopharyngitis                                          4 (9.5)          10 (24.4)    9 (22.5)     9 (22.5)     5 (26.3)
   Cough                                                    2 (4.8)          2 (4.9)      0            0            0
   Productive cough                                         2 (4.8)          0            0            0            0
   Constipation                                             2 (4.8)          2 (4.9)      3 (7.5)      0            0
   Bronchitis                                               1 (2.4)          0            0            3 (7.5)      1 (5.3)
   Upper respiratory tract infection                        1 (2.4)          1 (2.4)      0            2 (5.0)      1 (5.3)
   GERD                                                     0                2 (4.9)      1 (2.5)      0            0
   Back pain                                                0                0            3 (7.5)      0            0
  Drug-related AEs                                          7 (16.7)         5 (12.2)     4 (10.0)     5 (12.5)     0
  AEs leading to permanent discontinuation of study drugs                                                           
   Total SAEs                                               1 (2.4)          5 (12.2)     2 (5.0)      1 (2.5)      2 (10.5)

**Notes:** Data are presented as number of patients (percentage).

Includes COPD exacerbation or COPD worsening.

**Abbreviations:** AEs, adverse events; SAEs, serious adverse events; IND, indacaterol; GLY, glycopyrronium; TIO, tiotropium; GERD, gastroesophageal reflux disease.
